These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35034364)

  • 1. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
    Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
    Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
    Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
    Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
    Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
    Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
    Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
    Hopkins C; Mullol J; Khan AH; Lee SE; Wagenmann M; Hellings P; Fokkens W; Msihid J; Nair R; Kamat S; Nash S; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    Otolaryngol Head Neck Surg; 2024 Apr; 170(4):1173-1182. PubMed ID: 38156522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
    Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study.
    Hopkins C; Buchheit KM; Heffler E; Cohen NA; Olze H; Khan AH; Msihid J; Siddiqui S; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2022; 15():767-773. PubMed ID: 35698581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
    Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
    Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps.
    Khan AH; Reaney M; Guillemin I; Nelson L; Qin S; Kamat S; Mannent L; Amin N; Whalley D; Hopkins C
    Laryngoscope; 2022 May; 132(5):933-941. PubMed ID: 34437720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
    Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
    Hopkins C; Wagenmann M; Bachert C; Desrosiers M; Han JK; Hellings PW; Lee SE; Msihid J; Radwan A; Rowe P; Amin N; Deniz Y; Ortiz B; Mannent LP; Rout R
    Int Forum Allergy Rhinol; 2021 Jul; 11(7):1087-1101. PubMed ID: 33611847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
    Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
    Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.
    Domínguez-Sosa MS; Cabrera-Ramírez MS; Marrero-Ramos MDC; Dávila-Quintana D; Cabrera-López C; González Cuervo H; Benítez Del Rosario JJ; Carrillo-Díaz T
    Ann Med; 2024 Dec; 56(1):2411018. PubMed ID: 39364704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP.
    Lee SE; Amin N; Mannent LP; Bachert C; Gross G; Cho SH; Praestgaard A; Siddiqui S; Nash S; Kamat S; Khan AH; Jacob Nara JA
    Rhinology; 2023 Dec; 61(6):531-540. PubMed ID: 37453138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Smell Loss, Disease Burden, and Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal Polyps.
    Soler ZM; Patel ZM; Mullol J; Mattos J; Nash S; Xia C; Wang Z; Borsos K; Corbett M; Jacob-Nara JA; Sacks H; Rowe P; Deniz Y; Lane AP
    Am J Rhinol Allergy; 2025 Jan; 39(1):6-12. PubMed ID: 39300794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
    Dharmarajan H; Falade O; Lee SE; Wang EW
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
    Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
    J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.